Andreas Bock

Andreas Bock

Auto-generated profile, based on publicly available information

Andreas Bock

Institute of Pharmacology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2022 in Cell
Verified
Journal Article
Closed access
SASelma E. Anton
Selma E. Anton
CKCharlotte Kayser
Charlotte Kayser
IMIsabella Maiellaro
Isabella Maiellaro
KNKatarina Nemec
Katarina Nemec
JMJan Möller
Jan Möller
ABAndreas Bock
Andreas Bock

25 August 2020 in Cell
Verified
Journal Article
Closed access
ABAndreas Bock
Andreas Bock
PAPaolo Annibale
Paolo Annibale
CKCharlotte Konrad
Charlotte Konrad
AHAnnette Hannawacker
Annette Hannawacker
SASelma E. Anton
Selma E. Anton
MLMartin J. Lohse
Martin J. Lohse

1 January 2012 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAndreas Bock
Andreas Bock
NMNicole Merten
Nicole Merten
RSRamona Schrage
Ramona Schrage
CDClelia Dallanoce
Clelia Dallanoce
JBJulia Bätz
Julia Bätz
KMKlaus Mohr
Klaus Mohr
Seven transmembrane helical receptors (7TMRs) modulate cell function via different types of G proteins, often in a ligand-specific manner. Class A 7TMRs harbour allosteric vestibules in the entrance of their ligand-binding cavities, which are in the focus of current drug discovery. However, their biological function remains enigmatic. Here we present a new strategy for probing and manipulating conformational transitions in the allosteric vestibule of label-free 7TMRs using the M2 acetylcholine receptor as a paradigm. We designed dualsteric agonists as 'tailor-made' chemical probes to trigger graded receptor activation from the acetylcholine-binding site while simultaneously restricting spatial flexibility of the receptor's allosteric vestibule. Our findings reveal for the first time that a 7TMR's allosteric vestibule controls the extent of receptor movement to govern a hierarchical order of G-protein coupling. This is a new concept assigning a biological role to the allosteric vestibule for controlling fidelity of 7TMR signalling.

15 June 2020 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
JMJan Möller
Jan Möller
AIAli Isbilir
Ali Isbilir
TSTitiwat Sungkaworn
Titiwat Sungkaworn
BOBrendan Osberg
Brendan Osberg
CKChristos Karathanasis
Christos Karathanasis
MLMartin J. Lohse
Martin J. Lohse

1 July 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ABAndreas Bock
Andreas Bock
MBMarcel Bermudez
Marcel Bermudez
FKFabian Krebs
Fabian Krebs
Carlo MateraCarlo Matera
Carlo Matera
BCBrian Chirinda
Brian Chirinda
KMKlaus Mohr
Klaus Mohr
G protein-coupled receptors constitute the largest family of membrane receptors and modulate almost every physiological process in humans. Binding of agonists to G protein-coupled receptors induces a shift from inactive to active receptor conformations. Biophysical studies of the dynamic equilibrium of receptors suggest that a portion of receptors can remain in inactive states even in the presence of saturating concentrations of agonist and G protein mimetic. However, the molecular details of agonist-bound inactive receptors are poorly understood. Here we use the model of bitopic orthosteric/allosteric (i.e. dualsteric) agonists for muscarinic M2 receptors to demonstrate the existence and function of such inactive agonist·receptor complexes on a molecular level. Using all-atom molecular dynamics simulations, dynophores (i.e. a combination of static three-dimensional pharmacophores and molecular dynamics-based conformational sampling), ligand design, and receptor mutagenesis, we show that inactive agonist·receptor complexes can result from agonist binding to the allosteric vestibule alone, whereas the dualsteric binding mode produces active receptors. Each agonist forms a distinct ligand binding ensemble, and different agonist efficacies depend on the fraction of purely allosteric (i.e. inactive) versus dualsteric (i.e. active) binding modes. We propose that this concept may explain why agonist·receptor complexes can be inactive and that adopting multiple binding modes may be generalized also to small agonists where binding modes will be only subtly different and confined to only one binding site.

10 November 2013 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
ABAndreas Bock
Andreas Bock
BCBrian Chirinda
Brian Chirinda
FKFabian Krebs
Fabian Krebs
RMRegina Messerer
Regina Messerer
JBJulia Bätz
Julia Bätz
KMKlaus Mohr
Klaus Mohr